According to an article published in URO Today the belief that adjuvant androgen suppression therapy (AST) is associated with early deaths due to myocardial infarctions (MCIs) is not true. The belief that ASTs increases deaths from MCIs comes from the TROG 96.01 trial conclusions. Now there has been a retrospective, long term (ten year) meta-analysis [...]
My very dear friend and advocate supreme, Jan Manarite, from PCRI has sent me an update on MDV3100 (enzalutamide). As usual her information is important, so I thought I would pass it on today. • She points out that once the FDA approves MDV3100 (I am going to work on the assumption that it will [...]
Finally, we are getting a little common sense discussion about the role of PSA screening. Not to beat a dead horse, but as we all know the United Sates Preventive Task Force (USPTF) changed their rating of the PSA test from a D to a F. The result of this change is that many doctors, [...]
What are our goals as advanced prostate cancer survivors and what are the goals of our oncologists? Often they are not the same! This misalignment between our expectations and those of our clinicians is common, but inexcusable. These issues become clear when we look at issues surrounding our quality of life. The treatments for advanced [...]
There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval. I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news [...]